The Spanish pharmaceutical industry keeps betting on research with an investment of 972 million Euros in 2012. Namely, the investment reached 200 million Euros at the biotechnology sector, 20% of the total budget.

The most important allocation -479 million- was dedicated to clinical trials, most of them in clinical phase III. It must be highlighted that the expense in clinical research has increased 86% in the last nine years. 45% of the budget was dedicated to research contracts with hospitals, universities and public institutions, an activity that increased nearly 5% in 2012.

According to the data of the survey made to members of Farmaindustria, the number of R&D hiring decreased 3,6% in relation to 2011. However, the qualification of the employees is getting higher and higher: four out of five are graduates and doctors. In general figures, Spain is the fourth country in Europe in pharmaceutical workforce with nearly 40,000 jobs.

These data show that, in spite of the present economic situation and the measures of control of expenses, the pharmaceutical industry is still one of the main driving forces of  Spanish R&D.